Relapsed/refractory T cell acute lymphoblastic leukemia (T-ALL) is difficult to salvage especially in heavily pretreated patients, thus novel targeted agents are sorely needed.
Introduction
T cell acute lymphoblastic leukemia (T-ALL) occurs when mutated thymocytes that are destined for cell death survive and acquire additional mutations that promote full malignant transformation. 1 Cure rates, respectively, reach 60% in adults and over 80% in pediatric patients when treated with combination chemotherapy protocols. [2] [3] [4] However, resistance to first-line therapy is seen in 25% of children and more than 50% of adults, and the cohort that do respond to current ALL chemotherapy protocols often suffer from both acute and chronic toxic sideeffects despite treatment success. 5 Therefore, there is a need for the development of novel, non-chemotherapeutic treatments for T-ALL. 6, 7 In order to improve prognosis and mitigate side-effects seen with current chemotherapy treatments, it is crucial to evaluate the underlying molecular pathways that drive T-ALL and contribute to chemotherapy resistance. Over the last decade, the Janus Activating Kinase/ Signal Transducer and Activator of Transcription (JAK/STAT) pathway has emerged as playing a critical pathogenic role in several hematologic malignancies including T-ALL. 8, 9 Activation of JAK tyrosine kinases leads to the subsequent phosphorylation and activation of STAT transcription factors. Specifically, JAK1 or TYK2 are known to activate and phosphorylate STAT1 (pSTAT1), which is constitutively activated in leukemias and lymphomas. [10] [11] [12] Sanda et al 2013 demonstrated that many T-ALL cases are dependent upon the TYK2-STAT1-BCL2 pathway 1 . BCL2 is an anti-apoptotic protein that is pathologically overexpressed in several cancer types to increase survival [13] [14] [15] , including T-ALL. 16 These pathways allow for increased T-ALL proliferation through the JAK/STAT pathway and increased T-ALL survival through increased BCL2 expression.
Ruxolitinib is an FDA approved small molecule inhibitor that targets JAK1 and JAK2.
Ruxolitinib prevents the tyrosine phosphorylation of STAT1/3/5, which are downstream of cytokine receptors that drive T-ALL proliferation (e.g. IL -7) , and should function to inhibit the proliferative properties seen in T-ALL. Unfortunately for most patients, chronic therapy with ruxolitinib results in reactivation of JAK/STAT signaling and prevents T-ALL remission. 17 In these cases, BCL2 may also be hijacked and upregulated to promote survival of these cancer cells. 1 Venetoclax is a highly potent and specific BH3 mimitec which binds to the BCL2 protein without targeting platelets. This causes the downregulation of BCL2 and the eventual cell death of T-ALL. 16, 18, 19 The combination of ruxolitinib and venetoclax is emerging as a viable treatment option for relapsed disease. These drugs were previously utilized to treat IL-7 receptor alpha (IL7Rߙ)-mutated T-ALL, which prolonged survival in a preclinical model but ultimately all animals succumbed to leukemia. 20 Because the central nervous system (CNS) is a common site of T-ALL involvement, 2,21 one potential limitation of inhibiting these pathways in vivo is that it is unknown if these drugs can cross the blood-brain barrier (BBB). Also, the mechanism by which T-ALL would escape the combination of ruxolitinib and venetoclax is entirely unknown.
This study demonstrates that ruxolitinib and venetoclax work synergistically in vitro to treat T-ALL, but are not effective in vivo by showing for the first time the inability of these drugs to effectively cross the BBB and treat T-ALL in the CNS. CXCR4-CXCL12 has been implicated as a potential pathway that drives T-ALL infiltration into the CNS. [22] [23] [24] [25] By deleting the CXCR4 gene from T-ALL, we confirm previous findings that demonstrate prolonged survival in vivo with decreased overall and neurologic clinical scores. 22, 23 Thus, in the setting of CXCR4 inhibition, T-ALL CNS infiltration would be blocked and potentially ruxolitinib and venetoclax may be able to clear systemic disease.
Methods

Tumor cell lines
Jurkat (TIB-152) clone E6-1 and Loucy (CRL-2629) (ATCC Manassas, VA) were used as human T-ALL cell lines. Jurkat-GFP cell line was generated by transfecting 2x10 5 Jurkat cells using the Lonza 4D-Nucleofector X Unit (Basel, Switzerland). Nucleofector was used to deliver 1 μ g of px330 plasmid encoding for Cas9 protein and a gRNA for the AAVS1 locus and 1 μ g of an AAVS1-CAGGS-EGFP plasmid to serve as donor template. Nucleofection was carried out in SE buffer using a CL-120 pulse code for transfection. Cells were cultured in RPMI postnucleofection and sorted on a FACSAria for GFP+ cells. Cells were cultured in RPMI 1640 1x medium supplemented with 10% heat-inactivated FBS (Gemini bio-products, Sacramento, CA), L-Glutamine (2 mM), penicillin/streptomycin (100 μ /ml) at 37°C, 5% CO 2 and 95% humidity.
Excluding FBS, all other media ingredients were purchased from Corning, Corning, NY. All cell lines were mycoplasma tested and authenticated prior to use (IDEXX Bioresearch, Westbrook, ME).
In vivo T-ALL xenograft model
NOD/SCID/Il2rg tmwjl /Szj (NSG) breeder mice were purchased from Jackson Labs (Bar Harbor, ME) and bred internally at the UW Madison Mouse Breeding Core and Services (BRMS), Madison, WI. Mice were housed in accordance with the Guide for the Care and Use of Laboratory Mice and experiments were performed under an animal protocol approved by the institutional animal care and use committee. Both male and female mice aged 8-16 weeks were randomized into control or treatment groups. On Day +0, 2x10 6 Jurkat cells in 200 μ l of 1x PBS were injected intravenously into NSG mice to generate a xenograft T-ALL mouse model. Using flow cytometric analysis, at least 1% anti-human CD45 cancer burden was documented in the peripheral blood (usually day 5-7) before initiating treatments. Mice were orally gavaged once daily for 14-days with vehicle(s), 100μl 30 mg/kg/day ruxolitinib, 100μl 35 mg/kg/day venetoclax, or combination. Mice were monitored for survival, % weight change, and clinical symptoms of disease (activity, hunch, and hind-limb paralysis) using a modified scoring system (Supplementary Table 1 ). 
Ruxolitinib and venetoclax treatments
CRISPR-Cas9 deletion of CXCR4 in T-ALL
Jurkat cells were cultured in usual media supplemented with 25 ng/mL Amphotericin B (ATCC).
RNP delivery occurred via Electroporation. All CRISPR reagents were purchased from IDT, Coralville, IA. RNP complex was prepared immediately before electroporation. 
Statistical methods
GraphPad Prism version 7.0 for the Macintosh OS (GraphPad Software, San Diego, CA) generated all statistics. Data were expressed as mean ± SEM. For analysis of 3 > groups, a non-parametric ANOVA test was performed with the Bonferroni or Sidak's multiple comparisons post-test. Analysis of differences between two normally distributed test groups was performed using a two-sided Mann Whitney test. A p-value less than 0.05 was considered statistically significant.
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Results
Dysregulation of JAK/STAT and BCL2 in T-ALL patient samples
Secondary analysis of gene expression data from 14 different T-ALL patient samples showed that JAK1/2, STAT1/3/5 gene expression were increased as compared to normal tissue (NCI Oncogenomics St. Jude Leukemia Affy U133AB DB, https://pob.abcc.ncifcrf.gov/cgibin/JK). While JAK1 and STAT1 showed evidence of increased and decreased gene expression depending on the patient sample, JAK2 was consistently 1 to 2 standard deviations lower in expression while STAT3/5 were 1 to 2 standard deviations higher in expression as compared to controls. Furthermore, BCL2 expression was 2 to 3 standard deviations higher than normal tissue controls. (Figure 1A) 
Dosing of ruxolitinib or venetoclax alone decrease the survival and proliferation of T-ALL cells in vitro
To investigate the relevance of the JAK/STAT and BCL2 pathways on T-ALL proliferation and cell survival, Jurkat (mature T-ALL) and Loucy (early precursor T-ALL with high BCL2 expression) were assessed following treatment with either ruxolitinib or venetoclax. 15, 26 These cell lines were treated with a serial dose of ruxolitinib and venetoclax over the course of 72 h and evaluated using a trypan blue exclusion assay and MTT proliferation assay. Ruxolitinib and venetoclax were able to decrease the survival and proliferation of both Jurkat (Figure 1B-E) and Loucy (Supplementary Figure 1) 
Ruxolitinib and venetoclax synergistically decrease survival and proliferation of T-ALL cells in vitro
After determining that ruxolitinib and venetoclax individually affect survival and proliferation of T-ALL, T-ALL cells were treated with ruxolitinib and venetoclax in combination and evaluated again for survival and proliferation. A synergistic dose was determined by Compusyn software (Figure 2D ). This synergistic dose was then tested for survival and proliferation in comparison to single-dose and DMSO controls in both cell lines (Figure 2A, B, D; Supplementary Figure 2A, B) . The synergistic effect of ruxolitinib and venetoclax treatment was observed in all assays, and was significantly different from the DMSO and single-dose treatments of either ruxolitinib or venetoclax in both cell lines. In addition, the synergistic effect of the dual drug delivery as compared to individual drugs (or DMSO) was observed at all but one time point (p< 0.001 for survival and p <0.0001 for proliferation ( Figure 2D ). We next assessed both Annexin V and 7-AAD via flow cytometry and found increased Annexin V and 7-AAD in both cell lines, suggesting a synergistic benefit on viability (Figure 2E; Supplementary   Figure 2C ). The Jurkat cell line also showed a reduction of both survival for up to 5 days in culture utilizing Incucyte live-cell imaging technology (p< 0.0001 compared to no treatment) ( Figure 2C) .
Because the combination of ruxolitinib and venetoclax was effective in vitro but not in vivo, we next assessed whether or not ruxolitinib and venetoclax were acting on their intended targets, the JAK/STAT pathway and BCL2 family, in vitro. When given in combination, there were decreases in total STAT1 protein by western blot analysis (Figure 3A, B) and pSTAT1 expression by intracellular flow cytometry (Figure 3C ) as compared to single inhibitor and DMSO controls, while total STAT3 protein expression decreased in comparison to DMSO control ( Figure 3A) . STAT5 is not constitutively expressed in Jurkat cells, but the combination dose does lower STAT5 and pSTAT5 expression in other cell lines (data not shown). The combination dose also had an effect on several members of the BCL2 family of proteins, where the expression of the anti-apoptotic protein BCL2 decreased and the expression of pro-apoptotic proteins, BIM and BAK, increased ( Figure 3A, B) . These data suggest that ruxolitinib and venetoclax are acting on their intended targets in vitro. While both inhibitors are FDA approved and currently used in the clinic, there is no published data that shows if either inhibitor has the ability to effectively penetrate the CNS. Naïve mice were treated by oral gavage with the highest published in vivo single dose of either ruxolitinib (50 mg/kg) 29 or venetoclax (100 mg/kg), 15 the mice were then sacrificed at the known plasma-peak concentration for each inhibitor. The peripheral blood, spinal cord, and brain were then analyzed for the presence of either inhibitor by LC-MS-MS ( Figure 3D) . While approximately a third of the total plasma concentration of ruxolitinib was detected in the CNS, only a small fraction of venetoclax was detected in the spinal cord, with no detection in the brain. These data show that when administered in vivo at dosing of 30 mg/kg/day ruxolitinib and 35 mg/kg/day venetoclax, these drugs cannot penetrate the BBB, explaining why they fail to treat CNS T-ALL disease burden in the Jurkat in vivo model.
Ruxolitinib and venetoclax fail to treat T-ALL in vivo
T-ALL metastasizes to the CNS in part through the CXCR4-CXCL12 pathway in mice
Previously published data demonstrated that human T-ALL relapses to the CNS by exploiting the CXCR4-CXCL12 pathway. 22, 24, 31 Gene expression analysis of 5 pediatric T-ALL samples show CXCR4 is 1 standard deviation higher than in controls (NCI Oncogenomics pediatric tumor DB, https://pob.abcc.ncifcrf.gov/cgi-bin/JK) ( Figure 5A ). We verified that CXCR4 protein is highly expressed on the surface of Jurkat cells via flow cytometry ( Figure 5B ). Furthermore, using RNAScope and western blot analysis, we determined that CXCL12 mRNA and protein were expressed in the brain of NSG mice (Figure 5C, D) . These data suggest that mice injected with Jurkat cells could exploit the CXCR4-CXCL12 pathway, leading to CNS disease.
Using CRISPR-Cas9 technology we deleted the CXCR4 gene in Jurkat cells ( Figure   6A ). We then injected the CXCR4-KO, or no-guide control (NGC) Jurkat cells, into mice and monitored them for clinical symptoms of T-ALL. The NGC group developed rapid symptoms of CNS disease and had to be euthanized by day 35 (Figure 6B-D) . Surprisingly, CXCR4-KO mice remained healthy and developed no signs of T-ALL until day 65 (Figure 6C, D) . The CXCR4-KO mice did not become moribund until approximately 100 days after tumor inoculation ( Figure   6A ), 65-70 days after the NGC group succumbed to disease (p= 0.004).
Discussion:
Relapsed or refractory T-ALL remains a significant challenge to manage, especially because most patients are heavily pretreated with chemotherapy that causes significant end organ toxicity. Development of targeted therapies that inhibit pathways exploited by T-ALL to augment proliferation and survival may improve outcomes while also minimizing systemic toxicity. Prior studies involving RNA or whole genome sequencing of T-ALL samples identified the JAK/STAT pathway [32] [33] [34] and the BCL2 pathway 15 as dysregulated in these leukemias. In this study ruxolitinib, a JAK1/2 inhibitor and venetoclax, a potent BCL2 inhibitor independently decreased viability and proliferation of T-ALL in vitro. Further, combining these two inhibitors in vitro, achieved a synergistic effect demonstrating a greater increase in apoptosis and a decrease in proliferation compared to either inhibitor alone. This data confirmed findings previously demonstrated in T-ALL 20, 35, 36 and other cancers. [37] [38] [39] Ruxolitinib treatment alone has been considered a breakthrough therapy for myeloproliferative neoplasms but long-term studies have shown that this treatment is not curative and does not lead to molecular or pathological remission. This may be caused by the disease evading treatment and utilizing an alternative survival pathway; such as, the BCL2 pathway. While Senkevitch et al 2018 demonstrated a robust synergistic effect of combined JAK/STAT and BCL2 inhibition in vivo in IL7Rߙ+ T-ALL, all mice succumbed to T-ALL. Our study demonstrates for the first time that T-ALL progression after combined ruxolitinib and venetoclax treatment arises from CNS invasion through CXCR4, a previous homing pathway identified in untreated T-ALL cells. 22 The xenograft model of T-ALL with Jurkat cells presents as CNS disease with the cancer burden homing primarily into the spinal cord, rather than a primary systemic form where the burden is primarily in the bone marrow, spleen, and liver. 40 This xenograft model is clinically relevant given that CNS relapse is common for T-ALL, and is a strong driver for a poor prognosis. 41 The current standard of treating CNS leukemia is either by administering repeated doses of intrathecal chemotherapy, or giving irradiation to the neuro-axis. There is a great need to identify agents that are effective in the CNS when administered systemically. This study demonstrated for the first time that while ruxolitinib and venetoclax work synergistically in vitro they may be ineffective in vivo since they are unable to effectively cross the BBB and target CNS leukemia. LC-MS-MS demonstrated that ruxolitinib and venetoclax can be detected in the CNS, they are not at high enough concentrations to generate an anti-tumor effect at synergistic dosing. These data could be informative as future generations of these small molecule inhibitors may need to be engineered to allow for better CNS penetration.
Further we dissected the homing mechanism demonstrated with Jurkat cells in NSG mice. Several studies of human T-ALL demonstrated that CNS relapsed T-ALL occurs in part through the CXCR4-CXCL12 chemokine pathway. 22, 24, 25, 31 We confirmed for the first time that Jurkat cells utilize this pathway to escape treatment by ruxolitinib and venetoclax and infiltrate the CNS. CXCR4 is abundantly present on the surface of Jurkat cells, and the brain of NSG mice endogenously express CXCL12 mRNA and protein. Since murine CXCL12 can bind the human CXCR4 receptor 42 , human T-ALL can enter the CNS of NSG mice. Utilizing CRISPR-Cas9 to delete CXCR4 from the surface of Jurkat cells, we determined that CXCR4 plays a critical role in Jurkat cell homing to not only in the CNS but also non-CNS sites. CXCR4 deletion in T-ALL cells significantly delays lethality by 60-70 days while reducing neurological and overall clinical scores, showing that CXCR4 plays a critical role in T-ALL progression. CXCR4 has been identified as a key player in murine and human T-ALL establishment and progression. [22] [23] [24] The surface expression of CXCR4, which was demonstrated to be calcineurin dependent, is also essential to the leukemia-initiating cell (LIC) activity of T-ALL. 24 The absence of CXCR4 also results in migratory defects of T-ALL both in vitro and in vivo. 24 Furthermore, it has been demonstrated that CXCL12-producing vascular endothelial niches control the maintenance of T-ALL. 23 These niches are predominantly found in the bone marrow stroma but have also been discovered in the brain allowing infiltration into the CNS. 22, 23 Thus, inhibiting the CXCR4-CXCL12 pathway, such as with plerixafor, may be a means to prevent escape to the CNS after combination therapy with ruxolitinib and venetoclax.
Development of novel therapies for relapsed/refractory T-ALL is a high unmet need
given the poor prognosis of this cancer. Inhibiting the JAK/STAT pathway along with BCL2 using ruxolitinib and venetoclax is an effective treatment for relapsed T-ALL, but requires additional inhibition of CXCR4 to prevent CNS invasion and relapse after treatment. Currently, there are no studies investigating the link between the JAK/STAT-BCL2-CXCR4 pathways.
Future studies could consider targeting all 3 pathways as a means of inducing a sustained complete remission. Combination of ruxolitinib and venetoclax with cell-based therapies, like T or NK cells, could also be considered since immune effector cells can easily cross the BBB, but the impact of these drugs on these cell subsets will need to be explored carefully. 
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